ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
When chemists at Pfizer were looking to make a chiral homopropargyl β-amino alcohol en route to one of their clinical candidates, they wanted to improve their six-step route. Teaming up with researchers at continuous-flow research firm Snapdragon Chemistry, led by Yuan-Qing Fang and Matthew M. Bio, they made the desired compound in just two steps from commercially available starting materials (Angew. Chem. Int. Ed. 2017, DOI: 10.1002/anie.201704882). The synthetic route (shown) begins with lithiation of allene gas to produce allenyllithium, a compound so reactive that it’s usually made and used only at -78 °C. Such cryogenic conditions typically limit the use of allenyllithium. By using a continuous-flow process for the reaction, the chemists controlled the allene lithiation reaction so that they could use allenyllithium at about 0 °C. After lithiation, the compound undergoes transmetalation with zinc. The resulting intermediate is then used with a chiral (1S,2R)-N-pyrrolidinyl-norephedrine ligand to asymmetrically propargylate a β-amino aldehyde, producing the desired chiral homopropargyl β-amino alcohol.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X